Knockdown of Claudin-8 (CLDN8) Indicates a Link Between Breast Cancer Cell Sensitivity to Chemotherapeutics and Reveals a Potential Use of CLDN8 as a Molecular Diagnostic and Target for Therapy
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Claudin-8 (CLDN8) shows promise as a breast cancer biomarker. High CLDN8 predicts better outcomes with surgery or endocrine therapy but resistance to chemotherapy and anti-HER2 treatments.
Area Of Science
- Oncology
- Molecular Biology
- Biomarker Research
Background
- Breast cancer heterogeneity presents treatment resistance challenges.
- Claudin-8 (CLDN8), a tight junction protein, is a potential prognostic and predictive biomarker.
- Understanding CLDN8's role is crucial for personalized breast cancer therapy.
Purpose Of The Study
- To evaluate Claudin-8 (CLDN8) as a predictive biomarker for breast cancer treatment response.
- To investigate CLDN8 as a potential therapeutic target for overcoming treatment resistance.
- To correlate CLDN8 expression with clinical outcomes and patient survival.
Main Methods
- Analysis of CLDN8 gene expression in breast cancer patient cohorts.
- Association of CLDN8 levels with clinical outcomes and therapy response.
- Establishment of breast cancer cell models with altered CLDN8 expression to study drug sensitivity.
Main Results
- High CLDN8 expression correlated with improved disease-free survival, especially in estrogen receptor-negative patients (p=0.007).
- Elevated CLDN8 predicted better outcomes with surgery or endocrine therapy.
- Paradoxically, high CLDN8 was linked to poorer survival and resistance to chemotherapy and anti-HER2 therapies.
- In vitro CLDN8 knockdown decreased sensitivity to endocrine, HER2-targeted, and chemotherapeutic agents.
Conclusions
- Claudin-8 (CLDN8) is a significant prognostic factor in breast cancer.
- CLDN8 status can predict response to specific breast cancer treatments.
- CLDN8 may guide personalized therapy and serve as a target to overcome treatment resistance.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...